Insulin-Like Growth Factor-1 and Atherosclerosis: Mechanistic Insights and Clinical Implications

Clicks: 26
ID: 328978
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #39 of 192 articles by views in qjm : monthly journal of the association of physicians

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 192 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of mortality worldwide, with persistent residual risk despite optimal management of conventional risk factors. Insulin-like growth factor-1 (IGF-1), the principal effector of the growth hormone-IGF-1 axis, exerts dose-dependent dual effects on atherogenesis, yet its clinical value remains controversial and incompletely clarified. This review provides a concise overview of the core mechanistic basis of IGF-1 in atherosclerotic pathogenesis, synthesizes key epidemiological and clinical cohort evidence on the association between circulating IGF-1 and atherosclerotic cardiovascular events, evaluates its utility as a predictive and prognostic biomarker, and systematically summarizes the translational potential of IGF-1 axis-targeted interventions. Physiological IGF-1 concentrations confer endothelial protection, anti-inflammatory effects and plaque stability, whereas deviation to either excess or deficiency accelerates atherosclerotic progression. Circulating IGF-1 exhibits a non-linear association with ASCVD risk and prognosis, with routine clinical application currently limited by assay heterogeneity and metabolic confounders. Normalization of the IGF-1 axis at physiological levels delivers measurable vascular benefits, and pathway-selective modulators represent a promising direction for future translational research.
Reference Key
openalex_W7213329350 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lianjie Hou
Are you one of these authors? Claim your profile
Journal qjm : monthly journal of the association of physicians
Year 2026
DOI
10.1093/qjmed/hcag237
URL
https://doi.org/10.1093/qjmed/hcag237
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.